{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:57:37Z","timestamp":1789732657723,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1245\/s10434-024-15962-x","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T20:01:47Z","timestamp":1722369707000},"page":"8298-8307","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Irreversible Electroporation Margin Accentuation in Pancreaticoduodenectomy: A Propensity Score Matching Analysis"],"prefix":"10.1245","volume":"31","author":[{"given":"Joseph S.","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Heard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Brant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Malo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houssam","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Buell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiresh Rohan","family":"Jeyarajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,30]]},"reference":[{"key":"15962_CR1","unstructured":"National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Pancreatic Cancer. 2023. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html. Accessed 12 Apr 2024."},{"key":"15962_CR2","unstructured":"National Comprehensive Cancer Network. Pancreatic Adenocarcinoma (Version 1.2024). 2024. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf. Accessed 12 Apr 2024."},{"key":"15962_CR3","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.21037\/jgo-2020-slapc-04","volume":"12","author":"SO Bratlie","year":"2021","unstructured":"Bratlie SO, Wennerblom J, Vilhav C, Persson J, Rangelova E. Resectable, borderline, and locally advanced pancreatic cancer\u2014\"the good, the bad, and the ugly\" candidates for surgery? J Gastrointest Oncol. 2021;12:2450\u201360. https:\/\/doi.org\/10.21037\/jgo-2020-slapc-04.","journal-title":"J Gastrointest Oncol."},{"key":"15962_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/SLA.0b013e3180691579","volume":"246","author":"KY Bilimoria","year":"2007","unstructured":"Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173\u201380. https:\/\/doi.org\/10.1097\/SLA.0b013e3180691579.","journal-title":"Ann Surg."},{"key":"15962_CR5","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1097\/MPA.0000000000001634","volume":"49","author":"T Hackert","year":"2020","unstructured":"Hackert T, Klaiber U, Pausch T, Mihaljevic AL, B\u00fcchler MW. Fifty years of surgery for pancreatic cancer. Pancreas. 2020;49:1005\u201313. https:\/\/doi.org\/10.1097\/MPA.0000000000001634.","journal-title":"Pancreas."},{"key":"15962_CR6","doi-asserted-by":"publisher","first-page":"12705","DOI":"10.2147\/OTT.S220971","volume":"13","author":"A Barcellini","year":"2020","unstructured":"Barcellini A, Peloso A, Pugliese L, Vitolo V, Cobianchi L. Locally advanced pancreatic ductal adenocarcinoma: challenges and progress. Onco Targets Ther. 2020;13:12705\u201320. https:\/\/doi.org\/10.2147\/OTT.S220971.","journal-title":"Onco Targets Ther."},{"key":"15962_CR7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1093\/bjs\/znac353","volume":"110","author":"TF Stoop","year":"2023","unstructured":"Stoop TF, Mackay TM, Brada LJH, et al. Pancreatectomy with arterial resection for periampullary cancer: outcomes after planned or unplanned events in a nationwide, multicentre cohort. Br J Surg. 2023;110:638\u201342. https:\/\/doi.org\/10.1093\/bjs\/znac353.","journal-title":"Br J Surg."},{"key":"15962_CR8","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1097\/SLA.0b013e31823ac299","volume":"254","author":"N Mollberg","year":"2011","unstructured":"Mollberg N, Rahbari NN, Koch M, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254:882\u201393. https:\/\/doi.org\/10.1097\/SLA.0b013e31823ac299.","journal-title":"Ann Surg."},{"key":"15962_CR9","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.3390\/cancers13112511","volume":"13","author":"G Narayanan","year":"2021","unstructured":"Narayanan G, Daye D, Wilson NM, Noman R, Mahendra AM, Doshi MH. Ablation in pancreatic cancer: past, present and future. Cancers (Basel). 2021;13:2511. https:\/\/doi.org\/10.3390\/cancers13112511.","journal-title":"Cancers (Basel)."},{"key":"15962_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1245\/s10434-016-5676-3","volume":"25","author":"GG Kasumova","year":"2018","unstructured":"Kasumova GG, Conway WC, Tseng JF. The role of venous and arterial resection in pancreatic cancer surgery. Ann Surg Oncol. 2018;25:51\u20138. https:\/\/doi.org\/10.1245\/s10434-016-5676-3.","journal-title":"Ann Surg Oncol."},{"key":"15962_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/153303460700600106","volume":"6","author":"B Rubinsky","year":"2007","unstructured":"Rubinsky B, Onik G, Mikus P. Irreversible electroporation: a new ablation modality\u2013clinical implications. Technol Cancer Res Treat. 2007;6:37\u201348. https:\/\/doi.org\/10.1177\/153303460700600106.","journal-title":"Technol Cancer Res Treat."},{"key":"15962_CR12","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jimed.2023.07.005","volume":"6","author":"H Li","year":"2023","unstructured":"Li H, Zhou Y, Guo X, Zhang Q, Ding X. The effects of irreversible electroporation triggering anti-tumor immunity and the value of its combination with immunotherapy. J Interv Med. 2023;6:107\u201310. https:\/\/doi.org\/10.1016\/j.jimed.2023.07.005.","journal-title":"J Interv Med."},{"key":"15962_CR13","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s10439-020-02462-8","volume":"48","author":"B Mercadal","year":"2020","unstructured":"Mercadal B, Beitel-White N, Aycock KN, Castellv\u00ed Q, Davalos RV, Ivorra A. Dynamics of cell death after conventional IRE and H-FIRE treatments. Ann Biomed Eng. 2020;48:1451\u201362. https:\/\/doi.org\/10.1007\/s10439-020-02462-8.","journal-title":"Ann Biomed Eng."},{"key":"15962_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.surg.2022.07.033","volume":"173","author":"RCG Martin 2nd","year":"2023","unstructured":"Martin RCG 2nd, Schoen EC, Philips P, Egger ME, McMasters KM, Scoggins CR. Impact of margin accentuation with intraoperative irreversible electroporation on local recurrence in resected pancreatic cancer. Surgery. 2023;173:581\u20139. https:\/\/doi.org\/10.1016\/j.surg.2022.07.033.","journal-title":"Surgery."},{"key":"15962_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s11517-016-1603-9","volume":"55","author":"P Marsanic","year":"2017","unstructured":"Marsanic P, Mellano A, Sottile A, De Simone M. Irreversible electroporation as treatment of locally advanced and as margin accentuation in borderline resectable pancreatic adenocarcinoma. Med Biol Eng Comput. 2017;55:1123\u20137. https:\/\/doi.org\/10.1007\/s11517-016-1603-9.","journal-title":"Med Biol Eng Comput."},{"key":"15962_CR16","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/j.ejso.2021.05.024","volume":"47","author":"K Kundalia","year":"2021","unstructured":"Kundalia K, Hakeem A, Papoulas M, et al. Margin accentuation for resectable pancreatic cancer using irreversible electroporation: results from the MACPIE-I study. Eur J Surg Oncol. 2021;47:2571\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2021.05.024.","journal-title":"Eur J Surg Oncol."},{"key":"15962_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.surg.2014.06.058","volume":"156","author":"D Kwon","year":"2014","unstructured":"Kwon D, McFarland K, Velanovich V, Martin RC 2nd. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation. Surgery. 2014;156:910\u201322. https:\/\/doi.org\/10.1016\/j.surg.2014.06.058.","journal-title":"Surgery."},{"key":"15962_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1245\/s10434-015-5034-x","volume":"23","author":"MD Kluger","year":"2016","unstructured":"Kluger MD, Epelboym I, Schrope BA, et al. Single-institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients. Ann Surg Oncol. 2016;23:1736\u201343. https:\/\/doi.org\/10.1245\/s10434-015-5034-x.","journal-title":"Ann Surg Oncol."},{"key":"15962_CR19","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","volume":"262","author":"RC Martin","year":"2015","unstructured":"Martin RC, Kwon D, Chalikonda S, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation safety and efficacy. Ann Surg. 2015;262:486\u201394. https:\/\/doi.org\/10.1097\/SLA.0000000000001441. (discussion 492-4).","journal-title":"Ann Surg."},{"key":"15962_CR20","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/15533506231157442","volume":"30","author":"JMK Davis","year":"2023","unstructured":"Davis JMK, Salibi PN, Motz BM, Vrochides D, McKillop IH, Iannitti DA. Irreversible electroporation-assisted resection for locally advanced pancreas cancer. Surg Innov. 2023;30:332\u20139. https:\/\/doi.org\/10.1177\/15533506231157442.","journal-title":"Surg Innov."},{"key":"15962_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.sopen.2021.11.007","volume":"7","author":"SI Logarajah","year":"2022","unstructured":"Logarajah SI, Jackson T, Darwish M, et al. Whipple pancreatoduodenectomy: a technical illustration. Surg Open Sci. 2022;7:62\u20137. https:\/\/doi.org\/10.1016\/j.sopen.2021.11.007.","journal-title":"Surg Open Sci."},{"issue":"Suppl 2","key":"15962_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00292-013-1799-5","volume":"34","author":"CS Verbeke","year":"2013","unstructured":"Verbeke CS. Resection margins in pancreatic cancer. Pathologe. 2013;34(Suppl 2):241\u20137. https:\/\/doi.org\/10.1007\/s00292-013-1799-5.","journal-title":"Pathologe."},{"key":"15962_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","volume":"9","author":"KJ Labori","year":"2024","unstructured":"Labori KJ, Bratlie SO, Andersson B, et al. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2024;9:205\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(23)00405-3.","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"15962_CR24","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40:1220\u201330. https:\/\/doi.org\/10.1200\/JCO.21.02233.","journal-title":"J Clin Oncol."},{"key":"15962_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bioelechem.2014.07.010","volume":"100","author":"MB Sano","year":"2014","unstructured":"Sano MB, Arena CB, DeWitt MR, Saur D, Davalos RV. In-vitro bipolar nano- and microsecond electro-pulse bursts for irreversible electroporation therapies. Bioelectrochemistry. 2014;100:69\u201379. https:\/\/doi.org\/10.1016\/j.bioelechem.2014.07.010.","journal-title":"Bioelectrochemistry."},{"key":"15962_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/02656736.2018.1539253","volume":"36","author":"Q Shao","year":"2019","unstructured":"Shao Q, O\u2019Flanagan S, Lam T, et al. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int J Hyperthermia. 2019;36:130\u20138. https:\/\/doi.org\/10.1080\/02656736.2018.1539253.","journal-title":"Int J Hyperthermia."},{"key":"15962_CR27","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1093\/bja\/aeu256","volume":"113","author":"K Nielsen","year":"2014","unstructured":"Nielsen K, Scheffer HJ, Vieveen JM, et al. Anaesthetic management during open and percutaneous irreversible electroporation. Br J Anaesth. 2014;113:985\u201392. https:\/\/doi.org\/10.1093\/bja\/aeu256.","journal-title":"Br J Anaesth."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15962-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15962-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T14:07:17Z","timestamp":1728569237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15962-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,30]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["15962"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15962-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,30]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dhiresh Rohan Jeyarajah is a consultant for Angiodynamics, Ethicon, and Sirtex. Joseph S. Lim, Jessica Heard, Nick Brant, Juan Malo, Joshua Kong, Houssam Osman MD, and Joseph Buell have no conflicts of interest to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}